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Osteoporosis is a chronic disease with increasing incidence that predomi-
nantly occurs in female population. There are evidences that bisphosphonates, sele-
ctive estrogen receptor modulators, denosumab, teriparatide and strontium rena-
late, prevent vertebral fractures while alendronate, risedronate, zoledronic acid, de-
nosumab and strontium renalate prevent hip fractures. Although these drugs are 
effective in osteoporosis treatment, their use is limited by their side-effects and 
low-adherence. The aim of this review article was to compare efficacy of new drugs 
for osteoporosis currently in phase 2 and 3 clinical trials. After reviewing 57 articles 
available on PubMed and Scopus databases that evaluated efficacy of osteoporosis 
medications, 10 papers, that fulfilled the review criteria, were selected for the ana-
lysis. Finally, the efficacy of five drugs was compared. Efficacy was evaluated by the 
values of bone mineral density (BMD) and bone turnover markers (BTM). In all the 
analyzed articles the BMD increased and changes of BTM were noted. The highest 
increase of lumbar BMD from the baseline values was achieved after six months of 
subcutaneous application of 20 μg/day teriparatide (11.3%). The lowest increase of 
BMD in the same region was recorded after six months of risedronate therapy 100 
mg per os once monthly (2.1%). From ten selected articles, only one has reported da-
ta about fracture risk. 
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Osteoporosis is a chronic disease that predomi-
nantly occurs in the ageing female population (1-3). Ab-
out 30% of postmenopausal women have osteoporosis 
(3). It is estimated that consequently the number of fe-
males older than 50 years until the year 2050 will incre-
ase by 26% (4). Therefore, an increased incidence of 
osteoporosis among females is expected (4-7). The ma-
in goal of the prevention and therapy of osteoporosis is 
to prevent fractures, which otherwise can easily occur 
when the bones lose their strength and density (8). The 
cost of treatment of incident osteoporosis fractures is si-
milar to other chronic diseases such as stroke or heart 
disease (9). It is estimated that by the year 2025 the di-
rect treatment cost of osteoporotic fractures will reach 
approximately $25.3 billion per year (10).  
Discovery of detailed bone structure, roles of bo-
ne cells and pathogenesis of osteoporosis enabled de-
velopment of new therapeutic agents. The theories abo-
ut bone remodeling, the roles of bone cells (osteoclasts, 
osteoblasts and osteocytes) and bone remodeling  me-
diators (such as endocrine, paracrine, autocrine media-
tors, growth factors, immune mediators and eicosano-
ids) were quite developed during the past decade (11, 
12).  
The main classification of osteoporosis drugs into 
antiresorptive and anabolic medications is based on 
their mechanism of action. The antiresorptive medicati-
ons include the following drugs: bisphophonates, hor-
mones, selective estrogen receptor modulators (SER-
Ms), bazedoxifene and denosumab (11). The second 
class includes anabolic medication teriparatide (TPTD) 
that stimulates bone formation as parathyroid hormone 
analogs (PTH) (4, 11). Strontium ranelate has an uncle-
ar mechanism of action and could be classified as both 
anabolic and antiresorptive agent (4, 13). Nevertheless, 
there are several therapeutic groups under investigation: 
wingless signaling (Wnt) pathway proteins, cathepsin K 
inhibitors, cell adhesion molecules (CAMs), L-carnitine 
derivates, calcitonin homologs, growth hormones, and 
cultures of Streptomyces (14).  
This review is required because of expansion of 
new drugs which are currently in clinical trial phases 2 or 
3. Therefore, health care professionals need more infor-
mation about coming drugs in order to improve treat-
ment of osteoporotic patients. Also, there are no suffi-
cient reviews that outline comparisons of new therape-
utic agents’ efficiency.  
The aims of this review were to evaluate new dru-
gs for osteoporosis in clinical trial phases 2 and 3, and 





Search  S t ra tegy  
 
The primary literature search was conducted du-
ring August and September 2011 and followed by an 
update performed from December to January 2012. Ar-
ticles reviewed in this paper were identified through two 
electronic databases, PubMed and Scopus by combi-
ning the following MeSH terms: “osteoporosis”, “thera-
py” and “clinical trials phase (CTP) 2 and 3”. Only arti-
cles published in English after 2007 available as a full 
paper were considered for the review. The general inclu-
sion criterion was human study population aged 45 ye-
ars or more. Database PubMed allowed fine filter acco-
rding to the search criteria. For Scopus the authors need-
ed to match the key words with the inclusion criteria. 
Screening and selection of the articles were performed 
according to the Centre for Reviews and Dissemination 
guidance for undertaking reviews in health care, and Pre-
ferred Reporting Items for Systematic reviews and Meta-
Analyses statement (15, 16).  
After the initial selection of the papers, the au-
thors reviewed every title and abstract to identify if a stu-
dy meets the specified criteria. For the articles unavai-
lable in full length  the corresponding authors were con-
tacted. All collected articles were included into further a-
nalysis. 
 
Se lec t i on  o f  s tud ies  
 
Only articles that published the results of the CTP 
2 and CTP3 were included in the review process. Stu-
dies comparing an intervention to placebo or to another 
intervention were eligible for inclusion. The studies were 
selected if they met the endpoints, measurement of 
bone mineral density (BMD) and/or bone turnover mar-
kers (BTM). The articles which did not  measure BMD 
and/or percentage change of BMD compared to baseli-
ne values as an endpoint were excluded. Also, studies 
that examined drug efficacy in patients with secondary 
osteoporosis (breast, ovarian or prostate cancer) were ex-
cluded. There were no limits regarding the patient’s gen-
der, duration or type of the study, and pharmacological 
classification of drug for osteoporosis treatment. 
 
T ypes  o f  ou tcome measures  
 
Studies that reported values of BMD and BTM we-
re considered for this review. Studies that measured BMD 
by Dual-energy x-ray absorptiometry (DXA) on the total 
hip (TH), femoral neck (FN), lumbar spine (region L1-L4) 
(L), and forearm (distal radius) and presented BMD 
change in g/cm2 or as a percentage change (a differen-
ce between the values of BMD at the end of the study 
versus baseline value) were included.  
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Bone turnover is associated with the low BMD 
and high fracture risk (5). BMD changes in a short-term 
period can be well predicted by changes of biochemical 
markers (17). Changes in bone metabolism can be fa-
ster assessed by measuring of BTM than BMD. Therefore, 
early assessment of efficacy of osteoporosis therapy sho-
uld be followed by the values of BTM (18). Two groups 
of well-known BTM are used: bone formation and bone 
resorption markers. Frequently used biochemical bone 
formation markers are specific for collagen formation (os-
teocalcin (OC), bone-specific alkaline phosphatise (BSAP) 
and amino-terminal propeptide of type 1 collagen (PI 
NP)). Mostly used resorption markers are deoxypyrolidi-
noline, amino- and carboxy–terminal cross-linked telo-
peptides of type 1 collagen (NTX, CTX) (19). BTM can be 
measured in serum (BSAP, OC, CTX, PINP) or urine (NTX, 
Urinary deoxypyridinoline (DPD)) according to the refe-
rence methods.  
 
E f f i cacy  eva lua t ion  
 
Efficacy of medicines for osteoporosis treatment 
was examined as the percentage change of BMD or/and 
change in BTM (decrease during the therapy with anti-
resorptive agents or increase during the therapy with 
anabolic agents). The fracture risk, if reported, was also 




After the initial search of the PubMed and Sco-
pus databases, 57 articles were identified. Forty-two ar-
ticles were excluded by the title after abstract review or 
because they did not meet the required criteria. Nine 
articles were not available in full text format, however, 
four of them were obtained from the corresponding au-
thors. The final review included 10 articles (Figure 1). 
In selected articles, all studies recruited postme-
nopausal women for the analysis except one (20). Half 
of the articles published the results of multicenter inter-
national clinical trials. Measurement of BMD on L spine 
was performed in all the studies, and in some of them 
BMD was additionally measured on the forearm (F), pro-
ximal femur (PF), TH and/or trochanter (Trc). In all the 
studies, patients were taking additional supplements of 
calcium and/or vitamin D. Selected articles examined 
efficacy of five different drugs: denosumab, TPTD, arzo-
xifene, risedronate and bazedoxifene (Table 1). 
Value of BMD at the end of the study versus ba-
seline value is a useful indicator of medication efficacy, 
but only one article presented both values. All other stu-
dies showed their results as BMD percentage change 
without specifying what was the BMD value at the end 
of the study (21). Studies’ aims, main results, baseline 
BMD and percentage of its change at the end of the 




Figure 1. Article selection 
 
In the analyzed articles, all five drugs increased L 
BMD in the range from 2.1%  (risedronate 100 mg per 
os, once monthly during 6 months) (22) to 11.3%  (TPTD 
20 μg daily subcutaneous injection during 6 months) 
(Table 1) (20, 22, 23).   
Two studies demonstrated that after one-year tre-
atment with denosumab (60mg subcutaneous (sc) in-
jection every 6 months) the increase of BMD was the hi-
ghest in L spine in comparison with other skeletal sites 
(21, 24). One-year treatment study conducted by Ken-
dler et al. showed that the improvement of BMD after 
denosumab treatment was significantly higher (3%, p 
<0.05) at the L site, as well as at the TH site (1,9%, 
p<0.001) in comparison to alentronate (70 mg once 
weekly) (24). Miller et al. showed a constant increase of 
the L BMD with the same doses of denosumab therapy 
during the two-year extension study (BMD T-score - 2,14 
in the beginning and -1,55 in the end of the study, 
without specified level of significance) (21). 
All three articles that described TPTD efficacy 
showed significant increase only for L spine (20, 23, 
25). As  TPTD is a peptide hormone, it cannot be given 
orally and currently can only be administered as a daily 
sc injection. A new transdermal administration of TPTD 
made its application more convenient. Increase of TH 
BMD was significant (p<0.05) after 6-month administra-
tion of 40 μg daily TPTD transdermal-patch (1.33% chan-
ge) in comparison to placebo-patch (-0.63% change), 
and 20 μg daily TPTD sc injection (0.09% change). Other 
daily TPTD transdermal-patch doses (20 μg and 30 μg), 
did not show significant improvement of BMD at TH re-
gion, unlike L region where all examined TPTD transder-
mal-patch doses showed significant improvement (~3% 
for dose of 20 μg; ~3.5% for dose of 30 μg; ~5% for 
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dose of 40 μg, p<0.001) in comparison to baseline va-
lues and placebo (25). Another study showed better re-
sults of daily sc. injection form of TPTD in TH region. In-
crease of BMD at the TH (2.66%, p<0.001) was stati-
stically significant after first 12 months of therapy in com-
parison to baseline. Follow-up therapy (from 12 to 24 
months), showed continuous but not statistically signifi-
cant increase of TH BMD (20).  
New monthly oral therapeutic regiment of rise-
dronate was also examined as a more convenient way 
of application. Doses of 100, 150 or 200mg once a 
month showed efficacy similar to standard 5 mg daily 
dose after a 6-month therapy. Percentage changes of L 
BMD was not significantly different between applications 
of risedronate daily regimen (~3%) and monthly regi-
mens: ~2% (100 mg monthly); ~3% (150 mg monthly); 
~3,4% (200 mg monthly) (22). Investigation of new the-
rapeutic regimen of risedonate therapy of 75 mg at two 
consecutive days a month showed similar efficacy (L 
BMD+3,4%) to standard daily dose (L BMD+3,6%) af-
ter one year of application (26).   
Arzoxifene (20 mg/daily, per os, during two years 
of application) showed a significant increase of BMD at 
the level of p<0.001 at the L and TH region (2.92%, 
2.19%, p<0.001) compared with placebo (27).  
Bazedoxifene (20 mg/daily and 40 mg/daily, per 
os, during 3 years of application) showed a similar effica-
cy as raloxifene 60mg compared with placebo (percen-
tage change in L spine was 2.21%, 2.38%, 2.96, p 
<0.001 respectively; percentage change in TH was 0.27 
%, 0.50%, 0.90, p<0.001, respectively) (27, 28).   
From 10 selected articles only one reported data 
about fracture risk. Silverman et al. have reported that 
bazedoxifene (20mg, 40mg daily) and raloxifene signifi-
cantly reduced the risk of new vertebral fractures after 
36 months of therapy compared to placebo (42%, 37%, 




This review presented efficacy of osteoporosis 
drugs that are currently in clinical trials phase 2 and 3. 
Beside efficacy of new drugs, some of the studies tested 
new dosing regimens, or new ways of application of exi-
sting drugs. All the reviewed studies showed that the 
examined drugs increased more BMD in L spine region 
than in the hip region.  
Denosumab has high specificity and affinity for 
RANKL (6, 11, 29), and pharmacokinetic properties that 
allow its application once per every six months (11). 
This dosing regimen enables better adherence. Denosu-
mab therapy (60 mg sc every 6 months) showed a mo-
dest efficacy. After six years of therapy with denosumab, 
the improvement in BMD was about 3% in L spine and 
1% in TH region (21). In the study conducted by Mc-
Clung et al. denosumab applied in different therapeutic 
regimens (6, 14 or 30 mg sc every three months or 14, 
60, 100, or 210 mg sc every six months) after 12 
months of therapy showed a similar efficacy (L spine: 
3.0-6.7%, TH: 1.9-3.6%) (30). The study conducted by 
Kendler et al. showed that after switching therapy from 
alendronate (70 mg weekly, per os) to denosumab (60 
mg/6 months, sc), increase of BMD in L and TH was si-
gnificantly (p<0.0001) higher during the 12-month the-
rapy (BMD % change in L spine: 1.85%, 3.03%, respec-
tively; and TH region: 1.05%, 1.90%, respectively). After 
switching, the adherence was better with 60mg/6 mon-
ths denosumab therapy. The interesting fact was that 
BTM at the end of the study reached almost the baseli-
ne value in subjects continuing on alendronate but not 
in  the denosumab group (24). Study conducted by Mill-
er et al. examined effects of denosumab discontinuation 
after a two-year treatment (210 mg/6months, sc). Dis-
continuation period lasted one year. At the end of that 
period BMD decreased by 6.6% at the L spine and 
5.3% at the TH. After discontinuation period, retreat-
ment was continued with denosumab sc 60 mg/6 mo-
nths dose for a period of one year. At the end of retreat-
ment period, BMD was increased by 9% in L spine and 
3.9% in the total hip compared to the baseline values 
(31).  
TPTD daily sc application, showed the best efficacy in 
BMD improvement  in all measured skeletal regions (LS, 
TH and FN) in comparison to all examined drugs in this 
review (20, 25). Study conducted by Miyauchi et al. de-
monstrated that treatment with TPTD 20 μg/day sc. inj 
constantly improved BMD during the two-year study 
period compared to baseline values (20). TPTD daily sc 
application was uncomfortable, thus a new formulation 
of TPTD as transdermal patches was developed. The be-
st results were achieved with 40 μg TPTD patch at the L 
spine (improvement about 5%) (25).    
Review study published in 2006 by Cramer et al. 
indicated that a half of the patients treated with bisfo-
sfonates on a daily bases discontinued treatment after 
one year of therapy (32). Poor adherence could be the 
main reason for such early discontinuation of treatment 
with bisfosfonates (33). Values of BTM are in correlation 
with adherence (34).  
Similar to daily bisphosphonates, 5 mg daily dose 
regime of risedronate could lead to low patients’ adhe-
rence (33). Delmas et al. showed that the efficacy of 
risedronate 75 mg orally in two consecutive days a month 
was similar to daily regimen in all studied skeletal regi-
ons (35). For the L region, monthly risedronate regimen 
with doses 100 mg and 150 mg showed slightly lower, 
but 200 mg higher efficacy than risedronate 5mg/daily. 
This study explored efficacy only at L spine (22). One mo-
re study presented similar efficacy in L spine of weekly 
(35 mg and 50 mg) risedronate treatment compared to 
5 mg daily regimen (36).  
Selective estrogen receptor modulators (SERMs) 
or estrogen agonists/antagonists demonstrated positive 
effects on both fracture reduction and breast cancer risk 
reduction (2), but negative effects on endometrial sti-
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mulation (37, 38). Second class of SERM, arzoxifene, 
lasofoxifene and bazedoxifene had positive effects on 
bone formation and a little effect on uterine stimulation 
(39-41). Published results showed positive effects of ar-
zoxifene on BMD and no significant side effects on ute-
rus and endometrium (27). Different doses of bazedoxi-
fene showed higher percentage change of BMD on L 
than on thoracic spine. Efficacy of basedoxifene was sli-
ghtly lower than efficacy of raloxifene. Bazedoxifene ha-
ve shown similar incidence of adverse events as place-
bo. Deep vein thrombosis, vasodilatation, leg cramps and 
breast cysts/fibrocystic breast disease were less com-
mon than with raloxifene therapy (28).  
Fracture risk is one of the most important outco-
mes of efficacy evaluation. It is necessary for further 
studies to display accurate information on fracture risks. 
 
L im i ta t i ons  
 
Several limitations were noted during the study 
review: a) only one study presented numerical values of 
BMD at the beginning and at the end of the study (21). 
Other studies presented graphical increase of BMD from 
the baseline values (without specified values) and per-
cent change of BMD at the end of the study. This might 
lead to conclusion bias: a) only one study that examined 
efficacy of basedoxifene and arzoxifene was considered 
in the review b) duration of reviewed studies was diffe-
rent, thus comparing the results could be inadequate; c) 
although the most of the analyzed studies had as a se-
cond aim the analysis of drug safety, in this paper we 
reviewed only efficacy of the drugs; d) only articles pu-
blished in English were included in the review.  
According to this analysis, almost all reviewed dru-
gs, with exception of TPTD, showed similar efficacy at the 
L skeletal region. The best results at all skeletal sites we-
re achieved with TPTD. Efficacy of all examined drugs was 
less in hip than in L spine. Taking into account the cost 
and complications during the treatment of patients with 
TH fractures, the search for a new potential drugs/way of 
application need to be continued. The main goal of new 
treatment should be improved efficacy in all skeletal regi-
ons especially in TH region. Also, when considering the 
efficacy of drugs, it is necessary to consider the cost-
effectiveness of potential treatments and fracture risk 
assessment.  
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Saže tak  
 
Osteoporoza je hronična bolest koja je sve više zastupljena i to pretežno kod osoba ženskog pola. 
Postoje dokazi da bisfosfonati, selektivni modulatori estrogenskih receptora, denosumab, teriparatid i 
stroncijum ranelat mogu da preveniraju prelom kuka. Iako su ovi lekovi efikasni u lečenju osteoporoze, nji-
hova upotreba je ograničena usled ispoljavanja neželjenih reakcija, a time i postojanja niske adherencije 
bolesnika. Cilj ovog preglednog rada bio je upoređivanje efikasnosti novih lekova za lečenje osteoporoze 
koji su trenutno u 2. i 3. fazi kliničkih istraživanja. Nakon pregleda 57 originalnih radova koji su imali za cilj 
da pokažu efikasnost lekova u lečenju osteoporoze, dostupnih na PubMed i Scopus bazi, za analizu je oda-
brano 10 radova koji su zadovoljili kriterijume za pretraživanje. Na kraju analize, poređena je efikasnost 
pet lekova. Efikasnost je evaluirana na osnovu vrednosti mineralne koštane gustine (BMD) i koštanih mar-
kera (BTM). Povećanje BMD vrednosti i promene u vrednostima BTM zabeležene su u svim radovima. Naj-
veće povećanje BMD (za 11,3%) lumbalnog skeletnog regiona postignuto je nakon šestomesečne subku-
tane terapije teriparatidom u dozi 20 μg dnevno. Najmanje povećanje BMD (za 2,1%) istog skeletnog regi-
ona zabeleženo je nakon šestomesečne per os terapije risedronatom u dozi od 100 mg jednom mesečno. 
Od deset analiziranih studija, samo je jedna prikazala podatke o riziku od frakture. 
 
Ključne reči: osteoporoza, terapija, efikasnost, 2. i 3. faza kliničkih istraživanja  
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